Literature DB >> 21737653

Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy.

Farshad Nassiri1, Michael D Cusimano, Bernd W Scheithauer, Fabio Rotondo, Alessandra Fazio, George M Yousef, Luis V Syro, Kalman Kovacs, Ricardo V Lloyd.   

Abstract

Endoglin (CD105) is an accessory receptor for transforming growth factor beta (TGF-β) and its expression is up-regulated in actively proliferating endothelial cells. Endoglin has been suggested as an appropriate marker for tumor-related angiogenesis and neovascularization. Several studies demonstrate the potential of endoglin in tumor diagnosis, prognosis, and therapy. This review details the structure and function of endoglin, and investigates the role of endoglin in angiogenesis and tumor diagnosis, prognosis, and therapy.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21737653

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  116 in total

1.  The sensitivity of human mesenchymal stem cells to vibration and cold storage conditions representative of cold transportation.

Authors:  N I Nikolaev; Y Liu; H Hussein; D J Williams
Journal:  J R Soc Interface       Date:  2012-05-23       Impact factor: 4.118

Review 2.  Structural Biology and Evolution of the TGF-β Family.

Authors:  Andrew P Hinck; Thomas D Mueller; Timothy A Springer
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

Review 3.  Genetic status of KRAS influences Transforming Growth Factor-beta (TGF-β) signaling: An insight into Neuropilin-1 (NRP1) mediated tumorigenesis.

Authors:  Sneha Vivekanandhan; Debabrata Mukhopadhyay
Journal:  Semin Cancer Biol       Date:  2018-02-02       Impact factor: 15.707

4.  CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells.

Authors:  Sarah-Katharina Kays; Kerstin B Kaufmann; Tobias Abel; Christian Brendel; Halvard Bonig; Manuel Grez; Christian J Buchholz; Sabrina Kneissl
Journal:  Stem Cells Dev       Date:  2015-01-20       Impact factor: 3.272

5.  Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line.

Authors:  Xueliang Wang; Yunjiang Liu; Kaixuan Zhou; Geng Zhang; Feifei Wang; Jingwen Ren
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  The role of microvessel density, lymph node metastasis, and tumor size as prognostic factors of distant metastasis in colorectal cancer.

Authors:  Tomonari Cho; Eisuke Shiozawa; Fumihiko Urushibara; Nana Arai; Toshitaka Funaki; Yusuke Takehara; Sakiko Tazawa; Masashi Misawa; Mayumi Homma; Tomoko Norose; Mutsuko Omatsu; Hideyuki Miyachi; Toshiko Yamochi; Toshiaki Kunimura; Genshu Tate; Fumio Ishida; Shin-Ei Kudo; Masahumi Takimoto
Journal:  Oncol Lett       Date:  2017-03-31       Impact factor: 2.967

7.  Differential in vivo biodistribution of 131I-labeled exosomes from diverse cellular origins and its implication for theranostic application.

Authors:  Mohammad H Rashid; Thaiz F Borin; Roxan Ara; Kartik Angara; Jingwen Cai; Bhagelu R Achyut; Yutao Liu; Ali S Arbab
Journal:  Nanomedicine       Date:  2019-08-01       Impact factor: 5.307

Review 8.  Commonly used mesenchymal stem cell markers and tracking labels: Limitations and challenges.

Authors:  Ching-Shwun Lin; Zhong-Cheng Xin; Jican Dai; Tom F Lue
Journal:  Histol Histopathol       Date:  2013-04-16       Impact factor: 2.303

9.  Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance.

Authors:  S Krishna Priya; Kishore Kumar; K R Hiran; M R Bindhu; Rohit P Nagare; D K Vijaykumar; T S Ganesan
Journal:  Int J Clin Oncol       Date:  2016-08-27       Impact factor: 3.402

10.  Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo.

Authors:  Denada Dibra; Abhisek Mitra; Melisa Newman; Xueqing Xia; Jeffry J Cutrera; Mihai Gagea; Eugenie S Kleinerman; Guillermina Lozano; Shulin Li
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.